Dupilumab Efficacy in Patients with Type 2 Asthma with and without Elevated Blood Neutrophils

Figure 4

(a–d) Change in annualized severe exacerbation rates over the treatment period and change from baseline in prebronchodilator FEV₁ at Week 52 by baseline blood eosinophils (Giga/L) in patients with ≥4,000 neutrophils/µL at baseline, with FeNO ≥ 20 ppb AND ≥4,000 neutrophils/µL at baseline, with <4,000 neutrophils/µL at baseline, and with FeNO ≥ 20 ppb AND <4,000 neutrophils/µL at baseline. CI = confidence interval; FeNO = fractional exhaled nitric oxide; FEV₁ = forced expiratory volume in 1 s; LS = least squares; ppb = parts per billion; q2w = every 2 weeks.

(a)

(b)

(c)

(d)